Evidence map›Paper›PMID 28411317›Full record

ArticlePediatric nephrology (Berlin, Germany)2017

Race, obesity, and the renin-angiotensin-aldosterone system: treatment response in children with primary hypertension.

Andrew M South, Lester Arguelles, Gal Finer, Craig B Langman

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04752293 (Pediatric Hypertension and the Renin-Angiotensin SystEm), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04752293 recruitingnot on this mapstarted 2021, after this paper: background citation

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage

TypeobservationalSponsorWake Forest University Health SciencesRan2021 to 2026Enrolled125ConditionsHypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction, Left Atrial Dilatation
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Andrew M SouthSection of Nephrology, Department of Pediatrics, Wake Forest School of Medicine, Brenner Children's Hospital, Winston Salem, NC, USA. asouth@wakehealth.edu.
Lester ArguellesSchool of Public Health, University of Illinois at Chicago, 1603 W. Taylor Street, Chicago, IL, 60612, USA.
Gal FinerDivision of Kidney Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Craig B LangmanDivision of Kidney Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Northwestern University · USBrenner Children's Hospital · USUniversity of Illinois Chicago · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPediatric primary hypertension (HTN) is increasingly recognized, but the effect of patient characteristics such as obesity and race on treatment outcomes is not well described. The renin-angiotensin-aldosterone system (RAAS) may also contribute to HTN. We hypothesized patient parameters of these factors, including baseline RAAS, influence blood pressure (BP) response to pharmacological treatment in HTN.

methodsThis was a retrospective cohort of 102 consecutive patients with HTN. Primary outcomes were changes per year in systolic and diastolic BP (SBP, DBP). Secondary outcome was change per year in left ventricular mass index (LVMI). We evaluated whether baseline plasma renin activity (PRA), aldosterone, renin-to-aldosterone ratio, overweight/obesity, race, initial drug choice, and multidrug therapy were associated with the outcomes using general linear regression models adjusted for confounding variables.

resultsRacially diverse (43% Hispanic, 28% black, 25% white) and predominantly overweight/obese (75%) patients were studied. Median length of follow-up was 14.5 months. Higher baseline aldosterone was associated with decreased SBP (-1.03 mmHg/year), DBP (-0.95 mmHg/year), and DBP z score (-0.07/year) during the study period. Higher baseline PRA was associated with decreased SBP z score (-0.04/year) and LVMI (-2.89 g/m

conclusionsPretreatment aldosterone and PRA predicted short-term follow-up BP and LVMI, especially in nonobese and white patients. The RAAS profile could guide treatment of HTN and suggests consideration of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers as first-line treatment options.

Indexed as

Racial GroupsRenin-Angiotensin SystemAdolescentAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive AgentsBlood PressureChildDrug Therapy, CombinationFemaleFollow-Up StudiesHumansHypertensionMaleObesityRetrospective StudiesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive AgentsAngiotensin-converting enzyme inhibitorsAngiotensin II receptor blockersBlood pressureChildrenRaceResistant hypertension

Identifiers

PMID28411317
OpenAlexW2606597589

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.